Long-term continuous infusion of anti-GD2 antibody CH14.18/CHO in relapsed/refractory neuroblastoma patients
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2051-1426
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Long-term continuous infusion of anti-GD2 antibody CH14.18/CHO in relapsed/refractory neuroblastoma patients ; volume:1 ; number:1 ; day:7 ; month:11 ; year:2013 ; pages:1-2 ; date:11.2013
Journal for ImmunoTherapy of Cancer ; 1, Heft 1 (7.11.2013), 1-2, 11.2013
- Creator
- Contributor
-
Siebert, Nikolai
Kietz, Silke
Müller, Ina
Schuster, Manfred
Janzek, Evelyne
Wiederkum, Susanne
Mutschlechner, Oliver
Loibner, Hans
SpringerLink (Online service)
- DOI
-
10.1186/2051-1426-1-S1-P244
- URN
-
urn:nbn:de:1111-2016072650293
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:54 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Lode, Holger
- Siebert, Nikolai
- Kietz, Silke
- Müller, Ina
- Schuster, Manfred
- Janzek, Evelyne
- Wiederkum, Susanne
- Mutschlechner, Oliver
- Loibner, Hans
- SpringerLink (Online service)
Other Objects (12)
Long-term, continuous infusion of single-agent dinutuximab beta for relapsed/refractory neuroblastoma: an open-label, single-arm, Phase 2 study
Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia
Autologous stem cell transplantation in tandem with Anti-CD30 CAR T-cell infusion in relapsed/refractory CD30+ lymphoma
Management of relapsed-refractory diffuse large B cell lymphoma
Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma
Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia
Update on the management of relapsed/refractory chronic lymphocytic leukemia
Post-infusion Costs Associated with Idecabtagene Vicleucel Treatment for Patients with Relapsed/Refractory Multiple Myeloma in the KarMMa Trial
Immunomonitoring of Stage IV Relapsed Neuroblastoma Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation and Subsequent GD2 (ch14.18/CHO) Antibody Treatment
Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia
Daratumumab Plus Carfilzomib: An Optimistic Approach in Relapsed/Refractory Multiple Myeloma
Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond
Long-term, continuous infusion of single-agent dinutuximab beta for relapsed/refractory neuroblastoma: an open-label, single-arm, Phase 2 study
Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia
Autologous stem cell transplantation in tandem with Anti-CD30 CAR T-cell infusion in relapsed/refractory CD30+ lymphoma
Management of relapsed-refractory diffuse large B cell lymphoma
Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma
Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia
Update on the management of relapsed/refractory chronic lymphocytic leukemia
Post-infusion Costs Associated with Idecabtagene Vicleucel Treatment for Patients with Relapsed/Refractory Multiple Myeloma in the KarMMa Trial
Immunomonitoring of Stage IV Relapsed Neuroblastoma Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation and Subsequent GD2 (ch14.18/CHO) Antibody Treatment
Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia
Daratumumab Plus Carfilzomib: An Optimistic Approach in Relapsed/Refractory Multiple Myeloma
Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond
Long-term, continuous infusion of single-agent dinutuximab beta for relapsed/refractory neuroblastoma: an open-label, single-arm, Phase 2 study
Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia
Autologous stem cell transplantation in tandem with Anti-CD30 CAR T-cell infusion in relapsed/refractory CD30+ lymphoma
Management of relapsed-refractory diffuse large B cell lymphoma
Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma
Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia
Update on the management of relapsed/refractory chronic lymphocytic leukemia
Post-infusion Costs Associated with Idecabtagene Vicleucel Treatment for Patients with Relapsed/Refractory Multiple Myeloma in the KarMMa Trial
Immunomonitoring of Stage IV Relapsed Neuroblastoma Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation and Subsequent GD2 (ch14.18/CHO) Antibody Treatment
Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia
Daratumumab Plus Carfilzomib: An Optimistic Approach in Relapsed/Refractory Multiple Myeloma